HC Wainwright reissued their buy rating on shares of CG Oncology (NASDAQ:CGON - Free Report) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $75.00 target price on the stock. HC Wainwright also issued estimates for CG Oncology's Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.60) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.44) EPS, FY2026 earnings at ($2.30) EPS, FY2027 earnings at ($1.81) EPS, FY2028 earnings at ($0.15) EPS and FY2029 earnings at $1.34 EPS.
A number of other equities research analysts have also commented on the company. TD Cowen started coverage on CG Oncology in a research report on Tuesday, January 7th. They issued a "buy" rating on the stock. Royal Bank of Canada restated an "outperform" rating and set a $66.00 price objective on shares of CG Oncology in a research note on Friday, December 6th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $55.00 price objective on shares of CG Oncology in a research note on Friday, March 7th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $63.88.
Read Our Latest Research Report on CG Oncology
CG Oncology Price Performance
CG Oncology stock traded down $1.74 during mid-day trading on Monday, reaching $17.00. 792,174 shares of the company traded hands, compared to its average volume of 671,167. The firm's fifty day moving average is $27.26 and its two-hundred day moving average is $31.48. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -11.97 and a beta of 1.24. CG Oncology has a fifty-two week low of $16.69 and a fifty-two week high of $46.99.
CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. As a group, equities research analysts predict that CG Oncology will post -1.31 earnings per share for the current year.
Insider Buying and Selling at CG Oncology
In other news, Director Leonard E. Post sold 1,000 shares of the firm's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $29.66, for a total transaction of $29,660.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Hedge Funds Weigh In On CG Oncology
Large investors have recently bought and sold shares of the business. Wellington Management Group LLP grew its holdings in CG Oncology by 274.4% in the fourth quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company's stock valued at $54,792,000 after purchasing an additional 1,400,251 shares during the period. California State Teachers Retirement System lifted its position in shares of CG Oncology by 115.3% during the 4th quarter. California State Teachers Retirement System now owns 38,768 shares of the company's stock valued at $1,112,000 after buying an additional 20,763 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in CG Oncology in the 4th quarter valued at $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in CG Oncology by 496.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,902 shares of the company's stock worth $3,611,000 after acquiring an additional 104,780 shares in the last quarter. Finally, Woodline Partners LP raised its position in CG Oncology by 3.8% during the fourth quarter. Woodline Partners LP now owns 628,885 shares of the company's stock worth $18,036,000 after acquiring an additional 22,987 shares during the period. Institutional investors and hedge funds own 26.56% of the company's stock.
CG Oncology Company Profile
(
Get Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
See Also
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
